Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 26508744)

Published in J Am Heart Assoc on October 27, 2015

Authors

Risto Kerkelä1, Johanna Ulvila2, Johanna Magga2

Author Affiliations

1: Department of Pharmacology and Toxicology, Research Unit of Biomedicine, University of Oulu, Finland (R.K., J.U., J.M.) Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Finland (R.K.).
2: Department of Pharmacology and Toxicology, Research Unit of Biomedicine, University of Oulu, Finland (R.K., J.U., J.M.).

Articles cited by this

(truncated to the top 100)

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998) 13.56

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62

A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci (1981) 6.39

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med (2000) 5.34

Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47

A new natriuretic peptide in porcine brain. Nature (1988) 4.22

The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J (2000) 4.09

Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest (2012) 4.01

Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev (2005) 3.80

N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation (2002) 3.79

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78

Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science (1995) 3.61

Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature (1995) 2.90

Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res (2010) 2.89

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet (2010) 2.75

Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A (2000) 2.58

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest (2003) 2.37

Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32

Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol (2004) 2.31

Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science (1991) 2.25

Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J (2000) 2.24

The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol (2001) 2.10

Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes (2009) 2.03

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest (2001) 2.03

Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A (2001) 1.99

Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol (2006) 1.98

Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest (1998) 1.96

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res (2004) 1.95

Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev (2001) 1.94

Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation (2007) 1.93

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90

Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res (2000) 1.88

Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem (2009) 1.87

A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A (2001) 1.86

The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension (2010) 1.74

Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest (2005) 1.70

Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66

Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism. Cardiovasc Res (2009) 1.65

Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol (2013) 1.58

Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res (2010) 1.56

Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res (2013) 1.56

Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci U S A (2004) 1.55

Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension (2005) 1.53

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension (2006) 1.52

Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol (2007) 1.49

Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A (2003) 1.46

Natriuretic peptides and therapeutic applications. Heart Fail Rev (2007) 1.44

Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology (2003) 1.40

NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes (2013) 1.35

Brown adipose tissue in adult humans: a metabolic renaissance. Endocr Rev (2013) 1.34

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33

Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest (2012) 1.32

C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol (2005) 1.31

Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab (2011) 1.31

Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology (2007) 1.31

Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension (1995) 1.29

Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest (1999) 1.27

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24

Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation (2008) 1.23

Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem (2000) 1.23

Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2011) 1.23

The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys (2006) 1.22

Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest (1995) 1.21

Cardiac hormones as diagnostic tools in heart failure. Endocr Rev (2003) 1.20

C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol (1993) 1.19

Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A (2006) 1.18

Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem (2004) 1.15

Molecular regulation of the brain natriuretic peptide gene. Peptides (2005) 1.14

The natriuretic peptide/guanylyl cyclase--a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest (2009) 1.13

Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circ Res (2010) 1.12

Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem (2010) 1.11

Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart (2002) 1.11

GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J Biol Chem (2003) 1.07

Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation (2003) 1.06

Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol (2007) 1.06

Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol (2005) 1.05

Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol (1994) 1.05

Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem (1996) 1.04

Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation (2008) 1.04

Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol (2000) 1.02

Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation (2005) 1.02

Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation (2005) 1.01

Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol (2012) 1.00

Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem (2005) 1.00

Myocardin-related transcription factor A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Mol Cell Biol (2010) 1.00

Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail (2007) 0.99

Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol (2011) 0.98

Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail (2014) 0.98

Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension (2009) 0.97

Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res (1995) 0.97

Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. J Neurosci (2013) 0.96

Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol (2013) 0.95

Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol (1998) 0.95

Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem (2011) 0.95

Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol (2011) 0.95

Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol (2009) 0.95

The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology (2010) 0.94

Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation (2003) 0.94